News

July 9, 2025

APY Therapeutics is pleased to announce it has received a Catalyst Research and Development Voucher Award from the New Jersey Commission on Science, Innovation, and Technology. The award will fund mouse MRSA lung infection dose-escalation efficacy studies of APY409/461 and close analogs for candidate selection.

July 3, 2025

PCT patent application PCT/US24/61654 (filed December 26, 2024) by APY Therapeutics Founder and CEO Richard H. Ebright was published as WO/2025/144774. The patent application discloses current top compound APY409/461 and close analogs.

June 2, 2025

APY Therapeutics is pleased to announce it has received a Stage I award from INCATE (INCubator for Antibacterial Therapies in Europe).